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Simple Summary: Patients with epidermal growth factor receptor (EGFR) mutation-positive non-
small-cell lung cancer can have central nervous system (CNS) metastases during their disease course.
A high unmet medical need exists especially for patients with T790M-positive NSCLC whose disease
progressed after first-line EGFR-TKI. Osimertinib is a third-generation EGFR-TKI with selective
activity for both sensitizing and EGFR T790M mutations and has improved CNS activity over first-
and second-generation EGFR TKIs and chemotherapies. This study confirmed the clinical activity
and CNS efficacy of osimertinib in an unselected real-world population.
Abstract: Up to 40% of patients with epidermal growth factor receptor (EGFR) mutation-positive non-
small-cell lung cancer (NSCLC) may develop central nervous system (CNS) metastases throughout
their disease. Moreover, the first- and second-generation EGFR-tyrosine kinase inhibitors have limited
efficacy because of their poor blood–brain barrier permeability. Therefore, we conducted preplanned
analyses of ASTRIS, a clinical study of the third-generation EGFR-TKI osimertinib to demonstrate its
potential role in intracranial response efficacies. We retrospectively examined 89 NSCLC patients
with brain evaluation who were not amenable to curative surgery or radiotherapy and received
osimertinib upon confirmation of the presence of the T790M mutation. We collected the information
regarding patients’ baseline characteristics, baseline intracranial status, including leptomeningeal
metastases (LM), and intracranial responses measured by Response Evaluation Criteria in Solid
Tumors version 1.1, using independent central review. The median age was 60 years, and 69.7%
of the patients were female. Sixty-five patients (73.0%) had brain metastases (BM) at baseline and
nineteen patients (23.5%) had additional LM. Among patients with brain metastases, 24 (36.9%)
had ≥1 measurable brain metastases and 16 were evaluated for the objective response. In the CNS
evaluable for response set, the intracranial objective response rate (cORR) and disease control rate
(cDCR) were 62.5% (95% confidence interval (CI), 38.3–82.6%) and 93.8% (95% CI, 74.3–99.3%),
respectively. The median intracranial progression-free survival (cPFS) was 13.0 (95% CI, 7.21–18.8)
months, including patients with measurable and non-measurable BM or LM. Our cORR, cDCR, and
cPFS were comparable to those observed in previous clinical trials. The outcome of this study helps
to demonstrate the potential role of intracranial efficacies of osimertinib 80 mg administration in
T790M-positive advanced NSCLC with/without BM or LM.
Keywords: non-small-cell lung cancer; epidermal growth factor receptor; osimertinib; intra-
cranial response
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1. Introduction
Central nervous system (CNS) metastases are one of the most lethal complications
of epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer
(NSCLC). These metastases cause neurological dysfunction and cognitive impairment,
which negatively affect the patient’s quality of life and survival [1]. Treating NSCLC
metastases in the CNS with EGFR-tyrosine kinase inhibitors (TKIs) reduces CNS tumor
progression more than cytotoxic chemotherapies and radiation therapies [2]. However, the
activity of EGFR-TKIs is suboptimal for CNS cancer treatment, as EGFR-TKIs do not readily
cross the blood–brain barrier (BBB). The CNS is considered a sanctuary for metastases, and
many patients experience progressively worse symptoms due to CNS metastases [3].
Approximately 25% of patients with NSCLC have CNS metastases at the time of
diagnosis, and 50% of the patients develop it throughout the disease, even after EGFR-TKI
treatment [4]. Therefore, the treatment and prevention of CNS metastases is an important
clinical goal of managing EGFR-mutant NSCLC.
Osimertinib is a third-generation EGFR-TKI with selective activity for both sensitizing
and EGFR T790M resistance mutations. Preclinical studies showed that osimertinib had
higher BBB permeability than gefitinib or erlotinib [5]. Furthermore, osimertinib has
improved CNS activity over first- and second-generation EGFR TKIs and chemotherapies
in patients with previously treated EGFR T790M-positive NSCLC and treatment-naïve
EGFR-sensitizing mutation-positive NSCLC in phase III prospective trials [6,7].
The clinical activities and safety profiles of osimertinib were evaluated in ASTRIS trials
(ClinicalTrials.gov identifier: NCT02474355) including more than 450 patients enrolled in
Korea. This was a preplanned, exploratory analysis of CNS activity of osimertinib in the
Korean subgroup of the ASTRIS trial to evaluate the efficacy and safety of 80 mg orally, once
daily osimertinib. The study confirmed the clinical activity and a favorable safety profile
of osimertinib in a real-world population [8]. Further, we provide preplanned analyses of
osimertinib on the CNS metastases in a real-world cohort by blinded independent central
review (BICR).
2. Materials and Methods
2.1. Study Overview
Patients were enrolled from 31 institutes across Korea, the details of which were
published previously [9]. Patients with EGFR T790M mutation-positive NSCLC who
had previously been treated with at least one EGFR-TKI, and for whom the disease had
progressed, were invited to participate in the ASTRIS trial of osimertinib. Eligible patients
continued to receive osimertinib at the investigator’s discretion until disease progression
or until they experienced unmanageable drug-related toxicity.
2.2. Participants
All patients should have progressed on treatment with prior EGFR-TKI and with
confirmation of the presence of the EGFR T790M mutation and been enrolled in the ASTRIS
trial. Brain imaging by magnetic resonance imaging (MRI) or computed tomography (CT)
was optional in the ASTRIS trial; therefore, only patients with baseline brain imaging (from
within 3 months to enrollment date) were included in this ASTRIS CNS analysis study. All
submitted brain scans were assessed by independent radiologists (BICR).
We divided the patients into three groups according to their initial assessment: (1) pa-
tients without brain metastases, (2) CNS evaluable for response set (cEFR), which included
patients with one or more measurable CNS lesions, and (3) the CNS full analysis set (cFAS)
group, which included patients for whom BICR detected measurable and non-measurable
CNS metastases and patients with leptomeningeal metastases (LM).
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A CNS measurable lesion was defined as a lesion that measured ≥ 10 mm in diameter
by BICR. For patients with baseline CNS metastases, follow-up brain MRI and CT were
performed every 6 weeks if possible. For patients with no evidence of a baseline CNS
lesion, brain imaging was performed if clinically indicated.
2.3. Ethical Approval
The institutional review board approved ASTRIS at individual study centers (IRB
No. YCC4-2018-1006, NCC2019-0083, CBU2019-02-007, KBSMC2019-02-009, CNUHH-
2019-058). The trial was performed under the Good Clinical Practice guidelines and the
Declaration of Helsinki. All included patients provided written informed consent before
the enrollment of the trial.
2.4. Assessments and Statistical Analyses
The primary objective of this preplanned CNS analysis was intracranial progression-
free survival (cPFS). Secondary objectives were intracranial objective response rate (cORR),
intracranial disease control rate (cDCR), time to intracranial response (cTTR), duration of
intracranial response (cDoR), and time to new CNS metastases (TTCM). The additional
analysis included the assessment of leptomeningeal-response rate (LRR). All CNS efficacy
was assessed according to Response Evaluation Criteria in Solid Tumors (RECIST), version
1.1, by BICR. cPFS was defined as the time from the start of the ASTRIS study until the
date of objective intracranial disease progression or death (by any cause in the absence
of progression), regardless of whether the subject withdraws from randomized therapy
or receives another anti-cancer therapy prior to progression. cORR was defined as the
percentage of patients who have at least one confirmed complete intracranial response
(CR) or partial response (PR) prior to any evidence of progression (as defined by RECIST
version 1.1).
Data obtained up until progression, or last evaluable assessment in the absence of
progression, were included in the assessment of cORR. cDCR was defined as the proportion
of patients with CR, confirmed PR, or stable disease (SD). cTTR was defined as the time
from the start of the study until the first intracranial response. cDoR was defined as the
time from the first observation of a CNS response until the first observation of intracranial
progression or death. TTCM was defined as the time to the first detection of a new brain
metastases or leptomeningeal metastases. For patients with LM, response evaluation was
followed by RECIST 1.1 criteria as a non-target lesion. The data cutoff was 12 June 2019.
Descriptive statistics were used for all variables and endpoints. Kaplan–Meier methods
were used to calculate cPFS, cDCR, cTTR, cDoR, and TTCM.
3. Results
3.1. Patients
Of 89 patients treated with osimertinib, the median age was 60, and most were female
(69.7%). Seventy-seven patients met the Eastern Cooperative Oncology Group (ECOG)
performance status (PS) criteria of 0–1, and all patients had adenocarcinoma histology
harboring the EGFR T790M mutation (Table 1). Twenty-four patients did not have brain
metastases at initial assessment, and eleven patients missed their regular imaging follow-
up. Fifty-four patients were included in the cFAS group and sixteen patients in the cEFR
group (Figure 1). Thirty-eight patients had prior brain radiotherapy, and nineteen patients
showed LM disease on imaging (Table 1).
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Table 1. Patient characteristics at initial assessment.
Patient Characteristics
Age (years)


















No brain lesion 24 (27.0)
Baseline brain lesion *
No metastasis 24 (27.0)
Brain metastasis only 46 (51.7)
Brain metastasis with LM 19 (21.3)
Abbreviations: EGFR, epidermal growth factor receptor; ECOG PS, Eastern Cooperative Oncology Group
performance status; LM, leptomeningeal metastasis. * All the patients were evaluated with MRI.
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3.2. Osimertinib Efficacy 
For all patients, the median PFS and OS were 12.4 and 15.9 months respectively, in-
dicating poor patient prognosis after progressing to osimertinib treatment (Figure 2). In 
the patients with at least one measurable lesion in the brain, cORR was 62.5% (95% CI, 
38.3–82.6%). Zero (0%) and ten (63%) patients had a response of CR or PR, respectively. 
In the patients with any lesions in the brain, cORR was 38.9% (95% CI, 26.7–52.2%). Eleven 
(20.4%) and ten (18.5%) patients responded to CR or PR, respectively (Table 2). 
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3.2. Osimertinib Efficacy
For all patients, the median PFS and OS were 12.4 and 15.9 months respectively,
indicating poor patient prognosis after progressing to osimertinib treatment (Figure 2). In
the patients with at least one measurable lesion in the brain, cORR was 62.5% (95% CI,
38.3–82.6%). Zero (0%) and ten (63%) patients had a response of CR or PR, respectively. In
the patients with any lesions in the brain, cORR was 38.9% (95% CI, 26.7–52.2%). Eleven
(20.4%) and ten (18.5%) patients responded to CR or PR, respectively (Table 2).
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Analysis Set/Response 
cFAS (N = 54) 
n (%)(95% CI) 
cEFR (N = 16) 
n (%) (95% CI) 
CNS ORR, n (%) (95% CI) 21 (38.9) (26.7–52.2) 10 (62.5) (38.3–82.6) 
Complete response (CR) 11 (20.4) 0 (0) 
Partial response (PR) 10 (18.5) 10 (62.5) 
Stable disease (SD) 5 (9.3) 5 (31.3) 
Progressive disease 2 (3.7) 1 (6.2) 
non-CR, non-PD † 26 (48.1) - 
CNS DCR n (%) (95% CI) 52 (96.3) (88.6–99.2) 15 (93.8) (74.3–99.3) 
CNS DoR §   
Median, months (95% CI) 12.1 (8.5–15.8) 7.6 (NC–17.8) 
Time to onset of response   
Median, weeks (interquartile 
range) 8.6 (7.7–26.0) 7.7 (7.0–8.6) 
≤ 9 weeks, No. (%) 12 (57.1) 8 (80.0) 
Abbreviations: cEFR, CNS evaluable for response set; cFAS, CNS full analysis set; CR, complete 
response; DCR, disease control rate; DoR, duration of response; NC, not calculable; ORR, objective 
response rate; PD, progressive disease; PR, partial response. † For patients with non-measurable 
lesions only, response could be classed as CR, non-CR, non-PD, or PD. § Duration of response is 
time from first documentation of CR/PR until date of progression or death in the absence of pro-
gression. 
For patients who received brain radiotherapy before osimertinib, cORR was 26.7% 
(cFAS, 95% CI, 13.5–44.1%) and 54.2% (95% CI, 34.7–72.7%) in patients with no prior brain 
radiotherapy (Table 3). In subgroups (with or without prior radiotherapy), cORR was sig-
nificantly higher in patients without prior radiotherapy (p = 0.039). Regarding types of 
radiotherapy, 20 patients had whole brain radiotherapy and 10 patients had focal radio-
therapy. Most patients with focal radiation progressed in non-irradiated fields (60%). 
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Table 2. CNS response to osimertinib.
Analysis Set/Response cFAS (N = 54)n (%)(95% CI)
cEFR (N = 16)
n (%) (95% CI)
CNS ORR, n (%) (95% CI) 21 (38.9) (26.7–52.2) 10 (62.5) (38.3–82.6)
Complete response ( R) 11 (20.4) 0 (0)
Partial response (P 10 (18.5) 10 62.5)
Stable disease (SD) 5 (9.3) 5 (31.3)
Progressive disease 2 (3.7) 1 (6.2)
non-CR, non-PD † 26 (48.1) -
CNS DCR n (%) (95% CI) 52 (96.3) (88.6–99.2) 15 (93.8) (74.3–99.3)
CNS DoR §
Median, months (95% CI) 12.1 (8.5–15.8) 7.6 (NC–17.8)
Time to onset of response
Median, weeks (interquartile range) 8.6 (7.7–26.0) 7.7 (7.0–8.6)
≤9 weeks, No. (%) 12 (57.1) 8 (80.0)
Abbreviations: cEFR, CNS evaluable for response set; cFAS, CNS full analysis set; CR, complete response; DCR,
disease control rate; DoR, duration of response; NC, not calculable; ORR, objective response rate; PD, progressive
disease; PR, partial response. † For patients with non-measurable lesions only, response could be classed as
CR, non-CR, non-PD, or PD. § Duration of response is time from first documentation of CR/PR until date of
progression or death in the absence of progression.
For patients who received brain radiotherapy before osimertinib, cORR was 26.7%
(cFAS, 95% CI, 13.5–44.1%) and 54.2% (95% CI, 34.7–72.7%) in patients with no prior
brain radiotherapy (Table 3). In subgroups (with or without prior radiotherapy), cORR
was significantly higher in patients wi hou prio radiotherapy (p = 0.039). R garding
type f radiotherapy, 20 patients had whole brain radiotherapy and 10 patients had focal
radiotherapy. Most patients with focal radiation progressed in non-irradiated fields (60%).
Table 3. CNS objective response rate in the cFAS by prior brain radiotherapy.
Treatment Patients with a Response *n (%) (95% CI)
Prior radiotherapy before randomization (n = 30) ** 8 (26.7) (13.5–44.1) 0.039
No prior radiotherapy before randomization (n = 24) 13 (54.2) (34.7–72.7)
Abbreviation: cFAS, CNS full analysis set. * Patients with non-measurable disease only are included. ** Median
interval from end of radiotherapy to CNS imaging was 5.95 months.
Of the 19 patients with LM, 2 patients had complete radiographic responses and 4 had
partial radiographic responses. The median best percentage change after initial assessment
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of CNS target lesion size was −32.3% (range, −100% to +1.3%) (Figure 3). In the cFAS and
cEFR groups, median cDoR was 12.1 months (95% CI, 8.5–15.8 months) and 7.6 months
(95% CI, not calculable (NC)–5.7 months), respectively. Median weeks to response was
8.6 weeks for cFAS and 7.7 weeks for cEFR.
Cancers 2021, 13, x FOR PEER REVIEW 6 of 10 
 
 
Table 3. CNS objective response rate in the cFAS by prior brain radiotherapy. 
Treatment 
Patients with a Response * 
n (%) (95% CI) p 
Prior radiotherapy before 
randomization (n = 30) ** 8 (26.7) (13.5–44.1) 0.039 
No prior radiotherapy before 
randomization (n = 24) 
13 (54.2) (34.7–72.7)  
Abbreviation: cFAS, CNS full analysis set. * Patients with non-measurable disease only are in-
cluded. ** Median interval from end of radiotherapy to CNS imaging was 5.95 months. 
Of the 19 patients with LM, 2 patients had complete radiographic responses and 4 
had partial radiographic responses. The median best percentage change after initial as-
sessment of CNS target lesion size was −32.3% (range, −100% to +1.3%) (Figure 3). In the 
cFAS and cEFR groups, median cDoR was 12.1 months (95% CI, 8.5–15.8 months) and 7.6 
months (95% CI, not calculable (NC)–5.7 months), respectively. Median weeks to response 
was 8.6 weeks for cFAS and 7.7 weeks for cEFR. 
  














































Figure 3. (A) Patient with LM disease who showed CR. (B) Best percentage change from baseline in target lesion size (CNS 
evaluable for response set). Best percentage change in target lesion size is the maximum reduction from baseline or the 
minimum increase from baseline in the absence of a reduction. 
Figure 3. (A) Patient with LM disease who showed CR. (B) Best percentage change from baseline in target lesion size (CNS
valuable for response set). B st percentage change in target lesion size is the maximu reduction from baseline or th
minimum increase from baseline in the absence of a reduction.
3.3. Concordance between CNS and Systemic Responses
In the cFAS, concordance between response (CR or PR) and nonresponse (SD or PD)
categories for cORR and systemic ORR was 61.1% (33/54). The proportion of patients with
systemic responses who also achieved a CNS response was 50% (15/30). Disagreements
between CNS and the systemic responses were driven by assessment of SD in the CNS
(including non-CR and non-PD), but the systemic assessment of PR (25.9%; 14/54), and
disagreement on PD was 16.7% (9/54).
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3.4. cPFS and Risk of CNS Progression
In the analyzable patients, the median cPFS was 11.8 months (95% CI, 8.7–14.8 months).
Based on a Kaplan–Meier analysis, the estimated proportion of patients alive and CNS
progression-free at 6 and 12 months was 72.2% (95% CI, 58.4–83.5%) and 48.2% (95% CI,
34.3–62.2%), respectively (Figure 4).
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Based on competing risk analysis, the estimated probability of observing a CNS
progression event at 3 months was 7.4% (95% CI, 2.1–17.9%), and 27.8% at 6 months
(95% CI, 16.5–41.6%) (Figure 3). Two patients had new CNS metastasis, which occurred at
26.0 and 18.6 months, respectively.
4. D scuss on
Osimertinib is the current standard treatment in patients with T790M-positive NSCLC,
whose disease has progressed following first-line EGFR-TKI treatment. In this study, using
the Korean CNS cohort (N = 466) of the ASTRIS study, we assessed the intracranial activity
of osimertinib in 89 patients with EGFR T790M-positive advanced NSCLC with available
rain scan at b seline.
This CNS analysis was preplanned, and neuroradiological BICR assessed S re-
sponses. The median cPFS of 11.8 months (95% CI, 8.7–14.8 months) and cORR of 38.9%
in cFAS we e consistent with previous reports [7]. In the cFAS, a h gh rate of agreement
between CNS and systemic response to osimertinib was observed. Disagreement between
CNS and the systemic response was primarily driven by assessment of SD in the CNS
but the systemic assessment of PR, in which case, clinical management is the same. These
results support the improvement in systemic response with osimertinib reported in the
previous study population, including those patients with CNS metastases [6,10].
In the preclinical study, osimertinib showed greater BBB penetration compared to
previous generation EGFR-TKIs and exhibited sustained metastatic brain tumor regression
in mouse and nonhuman primate models [5]. The enhanced BBB penetrance of osimertinib
compared to first- and second-generation EGFR-TKIs may explain the CNS responses
observed in patients with advanced NSCLC. A pooled analysis of two prospective phase II
trials resulted in a cORR of 54% and cDCR of 90% in cEFR [10]. In AURA3, cORR and cDCR
were 70% and 93% in the osimertinib cEFR arm, respectively [6]. However, these previous
studies are randomized controlled trials (RCTs) investigating the efficacy and safety of
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study drugs under well-designed, well-controlled, and standardized clinical conditions
in a highly selected patient population; in these contexts, the outcomes from RCTs may
not always reflect the real-world clinical practice. Patients may have severe comorbidities
or poor performance status (e.g., ECOG PS ≥ 2), which are generally exclusion criteria in
prospective clinical trials, or patients may have poor compliance, which is very different
from protocol-specified patient care.
Thus, with increasing recognition, researchers and regulatory authorities are paying
attention to the importance of real-world evidence and valuing the real-world data more
than before [11]. ASTRIS was the largest global study to evaluate the safety and effective-
ness of osimertinib in T790M-positive NSCLC in the real-world. The data regarding CNS
activity were not available globally; however, our Korean CNS subset may further our
understanding of the management of EGFR-mutant NSCLC brain metastases.
Our analysis adds to the evidence of CNS activity of osimertinib in T790M-positive
NSCLC in the real-world by providing real-world experiences and broadening the study
population. Additionally, though small, our study was a preplanned analysis, and CNS
responses were assessed by BICR rather than investigator-assessed analysis, making our
study more relevant.
Interpretation of CNS effects of osimertinib may be confounded by prior radiotherapy,
and some studies have found that the BBB is more permeable to EGFR-TKI after radiother-
apy, though others have not [12,13]. In the present analysis, CNS ORR with osimertinib
was higher in patients who received no brain radiotherapy compared with patients who
received prior radiotherapy. These results are inconsistent with AURA3 CNS analysis, in
which the opposite effect was observed [6], likely due to the limited patient numbers in our
study. Therefore, these data should be interpreted carefully. Regardless, osimertinib was
observed to elicit CNS responses irrespective of prior brain radiotherapy in most studies.
Several limitations exist in our study. A major one is the small sample size of the
subgroup analysis. Next, it was impossible to evaluate the CNS efficacy of osimertinib in
patients without CNS metastases at the initial assessment. In addition, a limited number
of patients were suspected to have LM only by imaging, with a lack of a cerebrospinal
fluid (CSF) study. This may attribute to the invasiveness and technical difficulty of the
procedure. Additionally, positive CSF cytology is known to be found on the initial lumbar
puncture in only 50% of patients with LM, which makes physicians hesitate to perform the
procedure for patients with bad performance status [14]. The role of osimertinib in treating
patients with LM originating from NSCLC is being actively investigated, as these patients
have a very poor prognosis with a median survival of 2–3 months [15]. The BLOOM study
indicated that osimertinib is tolerable and exerts activity and manageable tolerability with
160 mg once daily [16]. Further real-world investigations into the efficacy of osimertinib
treatment for LM patients are warranted.
5. Conclusions
In conclusion, the CNS outcomes in a Korean ASTRIS subset were consistent with
those of previous prospective trials [6,7]. Our findings confirmed the consistent CNS
bioavailability of osimertinib with fully matured OS and PFS for T790M-positive NSCLC
with disease progression with first-line EGFR-TKI. An area of unmet need exists for better
CNS penetration and efficacy.
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